Munich Amyloidosis RegistrY - Prospective long-term study of patients with cardiac amyloidosis.

Munich Amyloidosis RegistrY - Prospective long-term study of patients with cardiac amyloidosis. - MARY

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031433

Enrollment

500

Registered

2023-06-09

Start date

2021-10-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac amyloidosis E85.9

Interventions

Group 1: Patients with cardiac amyloidosis (all comer registry). In this observational clinical trial, we aim to study patients with cardiac amyloidosis at disease onset and longitudinal progression t

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - signed informed consent form - invasively or non-invasively confirmed cardiac amyloidosis

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Cardiac decompensation and death one year after initial diagnosis	—

Secondary

Measure	Time frame
- Baseline clinical, laboratory, echocardiographic, spiroergometric, and functional characteristics. - Change in baseline characteristics during follow-up with symptomatic and/or specific therapy - Serious adverse cardiovascular and cerebrovascular events (MACCE).	—

Countries

Germany

Contacts

Public ContactPatrick Fuchs

Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen

fuchsp@dhm.mhn.de+49 89 1218 4005

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026